RxDoctor Payments Data

Connie Lee

Family · Jamestown, TNNPI 1215239231

Payments from drug & device makers

$1,160in general payments, 2019–2025

Across 72 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$217
  • Novo Nordisk$214
  • Lilly USA, LLC$198
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$133
  • AstraZeneca$98
  • Phathom Pharmaceuticals, Inc.$60
  • plus $238 from 9 others

What the payments were for

  • Food & beverage$1,14899%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,160 in reported general payments places this provider in the 65th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$173,205
Medicare patients
208
Services billed
6,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide60$69,882
EliquisApixaban100$69,527
OzempicSemaglutide45$66,383
VraylarCariprazine Hcl23$34,000
JardianceEmpagliflozin47$31,189
MounjaroTirzepatide18$23,683
XareltoRivaroxaban28$21,140
ViberziEluxadoline12$17,984
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$17,236
LinzessLinaclotide23$15,961
Combivent RespimatIpratropium/Albuterol Sulfate23$14,821
Tresiba Flextouch U-100Insulin Degludec15$13,805
Breo ElliptaFluticasone/Vilanterol14$11,457
Tiotropium Bromide16$8,102
InvokanaCanagliflozin12$7,699

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$198$93,56578 claims
AbbVieVraylar, Viberzi, Linzess$217$67,94558 claims
Novo NordiskOzempic, Novolog$214$67,93463 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$41$34,81247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,706 family providers in Tennessee.

Other family in Jamestown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →